EVOTEC SE INH O.N.
Commented by Armin Schulz on June 2nd, 2025 | 07:10 CEST
Bayer, Vidac Pharma, Evotec – Grab your share of the USD 866 billion oncology jackpot
Oncology is undergoing an unprecedented revolution. With a projected market volume of USD 866 billion by 2034 and annual growth of 11%, AI-driven diagnostics, personalized gene therapies, and precision medicine are driving this boom. Rising disease rates worldwide are fueling investment, while technological leaps are making therapies more effective and opening up high-return opportunities. Three players aim to leverage this explosive momentum for their profitable future: Bayer, Vidac Pharma, and Evotec.
Read
Commented by Fabian Lorenz on May 29th, 2025 | 07:10 CEST
Rheinmetall unstoppable! Evotec shorted! Sensational news at Vidac Pharma! And what is BioNTech doing?
Sensational news at Vidac Pharma. Last year's biotech highflyer has published strong results for its cancer drug. The share price rose by 5% yesterday. Does this mean the consolidation is over? Analysts certainly see potential for a multiplication in value. Rheinmetall shares have gained over 200% this year alone. Analysts are raising their price targets and continue to recommend buying. Operationally, a lot is happening at the defense company. Meanwhile, Evotec has run out of steam operationally. The stock has become a plaything for takeover speculators and short sellers — who will win? BioNTech also wants to win the fight against cancer. Will the stock gain new momentum in the coming days?
Read
Commented by André Will-Laudien on May 27th, 2025 | 07:15 CEST
Up to 1500% with high tech and artificial intelligence – Incredible price movements at Evotec, NetraMark Holdings, and D-Wave
Artificial intelligence can now be found in all sectors of the economy. Search processes, validations, and historical comparisons now take place in a matter of seconds, and a dramatic leap in productivity is on the horizon. The capital markets have set themselves the task of evaluating these future processes. This is no easy task, as most topics cannot be viewed in isolation. Last week, renewed tariff threats led to a short-term price correction. These losses had to be offset yesterday, with political denials from the US sending share prices skyrocketing again. Under intense pressure, investors now have to decide whether investments promise short- or medium-term success. We use three examples to show how challenging this has become. Where are the opportunities and risks?
Read
Commented by André Will-Laudien on May 22nd, 2025 | 07:20 CEST
Caution! Takeover imminent at Evotec or BioNxt, tension remains high at Bayer and Valneva
In advanced stock market cycles, many investors wonder where returns can still be made. Defense and high tech have raced ahead, and a sector rotation remains, particularly in favor of biotech. Despite substantial gains in major indices such as the DAX 40, up nearly 20%, the Nasdaq Biotech Index (NBI) is still down nearly 7%. The excitement is mounting, as some stocks are heading north and delivering better-than-expected figures. From an analytical perspective, Evotec and BioNxt are so undervalued that a takeover can no longer be ruled out. Bayer has issued a strong statement to the US courts, and Valneva is set to outperform its previous year's Q1 figures significantly. Time for an update: Where are the buying opportunities?
Read
Commented by André Will-Laudien on May 20th, 2025 | 07:10 CEST
Where will the biotech winner of 2025 come from? Evotec, Bayer, BioNTech, Vidac Pharma, and Pfizer under stock review
With new announcements coming out of Washington daily, the stock market carousel is spinning faster and faster. The direction is no longer uniformly upward, but deeper corrections, such as those seen in April, offer good entry opportunities. While the DAX 40 index reached a new all-time high yesterday at 23,977 points and has already recorded 27% growth in 2025, the Nasdaq Biotech Index (NBI) has lost a full 7.2% over the past six months. We have examined several interesting sector players and identified both opportunities and risks. In short, careful selection is once again key!
Read
Commented by Fabian Lorenz on May 12th, 2025 | 07:05 CEST
Gold at USD 6,000 and takeover rumors: Evotec, Barrick Gold, and Desert Gold shares
Evotec shares shot up by over 10% on Friday. Is it due to the payment from the Gates Foundation? Or is there a new attempt to buy German biotech companies soon? Desert Gold is a hot takeover candidate in the gold sector. The Canadians aim to expand their resources to 2 million ounces and start production soon. Analysts at GBC Research believe the share price could multiply. GBC's estimates are based on a gold price of USD 2,300. Currently, the precious metal is trading above USD 3,000. According to experts, USD 6,000 is even possible. In that case, even Barrick could strike it rich. However, the latest first-quarter report failed to provide new momentum for the stock. Are acquisitions needed?
Read
Commented by Armin Schulz on May 7th, 2025 | 07:10 CEST
Evotec's AI gold mine, Defence Therapeutics' billion-dollar markets, Novo Nordisk's diet revolution: How investors are profiting
The healthcare industry is undergoing radical change. Algorithms are accelerating drug discovery by years, billions are being poured into personalized therapies, and biotech stocks are celebrating on the stock markets. But this time, it is not just short-lived hype – the next era of medicine will be shaped by companies merging technology and biology. While AI-based platforms identify drug candidates in record time, pioneers are pushing ahead with groundbreaking approaches in oncology, immunology, and metabolic diseases. Three names stand out: Evotec, Defence Therapeutics, and Novo Nordisk.
Read
Commented by André Will-Laudien on May 5th, 2025 | 07:20 CEST
Biotech is back with artificial intelligence! Evotec, NetraMark Holdings, Bayer, and BioNTech
Artificial intelligence has arrived in health research! Whenever large volumes of data need to be analyzed, patterns recognized, or results condensed, immense computing power is required. The goal is to detect complex structures, automate processes, and make real-time decisions. The use of AI in medicine and pharmaceutical development is making good progress because time and high validation capability are key here. Some companies have already recognized the signs of the times and are working hard on the new technologies. On the stock market, this is often the starting signal for significantly higher valuations. Evotec, Bayer, and BioNTech are well-known European players, while Canadian company NetraMark Holdings has seen its share price increase sevenfold since fall 2024. What is behind this surge?
Read
Commented by Armin Schulz on May 1st, 2025 | 07:05 CEST
AI race in a billion-dollar market: How are Evotec, NetraMark Holdings, and Novo Nordisk doing in the race?
The pharmaceutical industry is undergoing a seismic change! Algorithms are replacing microscopes, and data pools are becoming the new pipeline for therapeutic breakthroughs. As billions are poured into artificial intelligence (AI), the battle is raging to crack the code for the next drug revolution – and to avoid drowning in a sea of data. Innovators like NetraMark are using machine learning to demystify clinical trials, while giants like Novo Nordisk are reinventing diabetes treatments with digital twins. Evotec is using AI-driven approaches to drug discovery. Who will succeed in bridging the gap between hype and healing?
Read
Commented by Fabian Lorenz on April 25th, 2025 | 07:00 CEST
RENK BEFORE TAKEOVER? Will Evotec and AI gem NetraMark be swallowed up?
Is RENK on the verge of a takeover? In any case, the antitrust authorities have approved the entry of a new major shareholder. Could the takeover of the gearbox manufacturer herald a consolidation in the European defense industry, as announced by the head of Hensoldt? So far, there have only been small acquisitions, such as those of Rheinmetall. There is also movement in the pharmaceutical and biotech sectors. The Trump tariffs are shaking up the industry. NetraMark's AI software helps reduce costs and save time in drug research. The AI insider tip's stock still appears cheap and could skyrocket amid takeover speculation. Evotec has also been repeatedly mentioned as a takeover candidate. Yesterday, a large milestone payment was reported. How are the shares performing?
Read